Ignite Proteomics Completes Major Acquisition for Breast Cancer Diagnostics
Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (NASDAQ: BACK), has finalized an important acquisition that strengthens its position in the field of breast cancer diagnostics. The company has successfully transferred the Proprietary Laboratory Analyses (PLA) code 0249U from Theralink Technologies, Inc., marking a significant enhancement to its advanced proteomic breast cancer assay.
The Significance of PLA Code 0249U
The newly acquired PLA code 0249U plays a crucial role in the landscape of diagnostics. This code is recognized within Medicare’s Clinical Laboratory Fee Schedule (CLFS), which helps to establish serious credibility for the test in healthcare billing systems. The acquisition enables Ignite to validate the assay effectively, allowing for a smoother reimbursement process that empowers clinicians and patients alike.
Understanding the Importance of Proteomic Testing
PLA codes, such as 0249U, are essential for validating new diagnostics. They help secure reimbursement for the tests, which can often be a major hurdle in launching a new assay. According to the latest Medicare data, 0249U has a reimbursement value of $2,219.13, indicating the code's vital role in ensuring that innovative diagnostic tests are implemented in clinical settings.
Faith Zaslavsky, CEO of Ignite Proteomics and IMAC Holdings, expressed her enthusiasm for this milestone, stating, "We are thrilled with this culmination of our efforts to integrate both the proprietary lab capabilities and the intellectual property underlying PLA code 0249U into Ignite Proteomics. This accomplishment strengthens our role in the proteomic diagnostics arena and propels us towards innovations in precision oncology."
Transforming Cancer Treatment with Proteomic Assays
The proteomic assay that now falls under the 0249U code offers a stark contrast to traditional genomic tests. It assesses functional protein activity rather than merely identifying the genes present in breast tumors. This innovative approach provides oncologists with actionable data regarding how patients could respond to targeted therapies, tailoring treatment plans to each individual’s unique biological profile.
Testing in a Certified Laboratory
The testing is performed in a laboratory that holds the highest accreditation – CLIA-certified, CAP-accredited, and NY State-approved – which guarantees adherence to rigorous quality standards. This assurance of quality is essential for gaining trust among healthcare providers and patients, as it underscores Ignite’s commitment to excellence in medical diagnostics.
Key Aspects of the Transaction
The transition of 0249U PLA Code from Theralink Technologies to Ignite Proteomics encompasses several key elements:
- **Ownership Transfer**: The PLA code is now under the control of IMAC Holdings and Ignite Proteomics, facilitating direct implementation in their diagnostics.
- **Medicare CLFS Pricing**: The established pricing of approximately $2,219 reinforces the financial viability of implementing this assay in clinical settings.
- **Coverage Guidance**: The MolDx coverage article A59636 provides clear guidance on billing and coverage for proteomic assays, streamlining the reimbursement process.
Traditionally, tests lacking a dedicated code often faced challenges with generic codes, leading to complexities in reimbursement. By acquiring this specific PLA code, Ignite Proteomics significantly alleviates these concerns, ensuring a straightforward understanding for payers about the specific test’s value.
Aiming for Broader Adoption
With the acquisition of PLA code 0249U, Ignite Proteomics aims to raise awareness and foster the adoption of its proteomic assay for breast cancer diagnostics. This decision is not merely a procedural change; it signifies a transformative moment for the company and the patients they serve. By evaluating the proteins and biological pathways that affect tumor response to treatments, Ignite can help healthcare providers deliver more personalized and effective care.
About Ignite Proteomics
Ignite Proteomics LLC is an innovative subsidiary of IMAC Holdings, focused on utilizing advanced Reverse Phase Protein Array (RPPA) technology in cancer diagnostics. Their work bridges a crucial gap that traditional gene-focused methods often leave unaddressed. By matching patients with the most suitable therapies based on specific protein markers, Ignite offers a more tailored approach to treatment.
About IMAC Holdings, Inc.
IMAC Holdings, Inc. is dedicated to enhancing patient outcomes through transformative healthcare solutions. With a strategic focus on innovative technologies and strategic acquisitions, the company remains committed to pioneering advances in personalized medicine. The company is in the process of rebranding and will soon operate under the name IMAC Holdings, Inc., DBA Ignite Sciences, Inc.
Frequently Asked Questions
What is the significance of the PLA code 0249U?
PLA code 0249U is critical for securing reimbursements and recognition of Ignite's advanced breast cancer diagnostic assays within healthcare systems.
How does Ignite's proteomic assay differ from traditional tests?
Unlike standard genomic tests that look solely at genetic information, Ignite's proteomic assay measures active protein functionality, providing more relevant treatment data.
What accreditation does Ignite's laboratory hold?
Ignite's laboratory is CLIA-certified, CAP-accredited, and NY State-approved, meeting high-quality standards for clinical testing.
How does the acquisition of 0249U affect patient access to testing?
The acquisition simplifies the billing process, potentially increasing patient access to personalized evaluations in cancer treatment.
What role does IMAC Holdings play in this acquisition?
IMAC Holdings oversees Ignite Proteomics and is committed to developing healthcare solutions that improve patient outcomes.
